Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Nicolaus Kröger(Universität Hamburg), Théo de Witte(Goethe University Frankfurt), Marie Robin(Universität Hamburg), Christof Scheid(Centrum für Integrierte Onkologie), Wolfgang Bethge(University of Tübingen), Boris V. Afanasyev(First Pavlov State Medical University of St. Petersburg), Giorgio La Nasa(University of Milan), Xavier Poiré(Universität Hamburg), Andreas Guenther(Universität Hamburg), Thomas Weber(Martin Luther University Halle-Wittenberg), Francesco Onida(Peter MacCallum Cancer Centre), Uwe Platzbecker(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Liisa Volin(Universität Hamburg), Marleen van Os(Universität Hamburg), Kai Hübel(University Hospital Cologne), Peter Dreger(Heidelberg University), Dominik Heim(University Hospital of Basel), Massimo Pini(Universität Hamburg), Simona Iacobelli(Universität Hamburg), Ronald Brand(Universität Hamburg), Stefano Guidi(Universität Hamburg), Ruzena Uddin(Universität Hamburg), Guido Kobbe(Heinrich Heine University Düsseldorf), Georg‐Nikolaus Franke(University Hospital Leipzig), Matthias Stelljes(University Hospital Münster)
Cited by 248
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist
|Blood|2003|717
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644